Spots Global Cancer Trial Database for ym155
Every month we try and update this database with for ym155 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| An Open-Label Study of YM155 + Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors | NCT00514267 | Prostate Cancer Tumors | YM 155 Docetaxel Prednisone | 18 Years - | Astellas Pharma Inc | |
| A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma | NCT01009775 | Melanoma | YM155 Docetaxel | 18 Years - | Astellas Pharma Inc | |
| An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155 | NCT00818480 | Prostate Cancer Melanoma Non-Hodgkin's L... | YM155 | 18 Years - | Astellas Pharma Inc | |
| A Study for the Treatment of Unresectable Stage III or Metastatic Stage IV Melanoma | NCT00281541 | Melanoma | YM155 | 18 Years - | Astellas Pharma Inc | |
| A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma | NCT01009775 | Melanoma | YM155 Docetaxel | 18 Years - | Astellas Pharma Inc | |
| A Clinical Pharmacological Study of YM155 After Intravenous Infusion in Patients With Advanced Cancer | NCT01023386 | Cancer | YM155 | 18 Years - | Astellas Pharma Inc | |
| A Study for the Treatment of Hormone Refractory Prostate Cancer (HRPC) in Patients Previously Treated With Chemotherapy | NCT00257478 | Prostate Cancer Cancer of Prost... Prostatic Cance... Cancer of the P... | YM155 | 18 Years - | Astellas Pharma Inc | |
| LUCY: A Study for the Treatment of Non-Small Cell Lung Cancer (NSCLC) in Patients Previously Treated With Chemotherapy | NCT00328588 | Lung Cancer Cancer of Lung Cancer of the L... Non-Small Cell ... Carcinoma, Non-... | YM155 | 18 Years - | Astellas Pharma Inc | |
| A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer | NCT01038804 | Breast Cancer | YM155 Docetaxel | 18 Years - | Astellas Pharma Inc | |
| A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment | NCT01007292 | Non-Hodgkin's L... | YM155 Rituximab | 18 Years - | Astellas Pharma Inc | |
| An Open-Label Study of YM155 + Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors | NCT00514267 | Prostate Cancer Tumors | YM 155 Docetaxel Prednisone | 18 Years - | Astellas Pharma Inc | |
| A Study for the Treatment of Unresectable Stage III or Metastatic Stage IV Melanoma | NCT00281541 | Melanoma | YM155 | 18 Years - | Astellas Pharma Inc | |
| A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer | NCT01038804 | Breast Cancer | YM155 Docetaxel | 18 Years - | Astellas Pharma Inc | |
| A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment | NCT01007292 | Non-Hodgkin's L... | YM155 Rituximab | 18 Years - | Astellas Pharma Inc | |
| A Phase I/II Study of Paclitaxel, Carboplatin and YM155 (Survivin Suppressor) in Subjects With Solid Tumors (Phase I) and Advanced Non-Small Cell Lung Carcinoma (Phase II) | NCT01100931 | NSCLC Solid Tumors | YM155 Carboplatin Paclitaxel | 18 Years - | National Institutes of Health Clinical Center (CC) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
